Our findings revealed distinct coexpression patterns of MET/ESR1 and MET/ESR2, each correlating with specific clinicopathologic features and clinical outcomes, thereby enriching the prognostic landscape of breast cancer. This evidence concerns the gene ESR2 and breast carcinoma.